AIM ImmunoTech (AIM) stock price, revenue, and financials

AIM ImmunoTech market cap is $9.6 m, and annual revenue was $367 k in FY 2018

$9.6 M

AIM Mkt cap, 13-Feb-2020

$61 K

AIM ImmunoTech Revenue Q3, 2019
AIM ImmunoTech Gross profit (Q3, 2019)-169 K
AIM ImmunoTech Gross profit margin (Q3, 2019), %(277%)
AIM ImmunoTech Net income (Q3, 2019)-2.9 M
AIM ImmunoTech EBIT (Q3, 2019)-3.2 M
AIM ImmunoTech Cash, 30-Sept-20199.6 M
AIM ImmunoTech EV4.6 M

AIM ImmunoTech Revenue

AIM ImmunoTech revenue was $367 k in FY, 2018

Embed Graph

AIM ImmunoTech Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

36.0k45.0k72.0k49.0k39.0k42.0k36.0k36.0k76.0k36.0k45.0k36.0k47.0k23.0k39.0k15.0k22.0k84.0k213.0k90.0k56.0k33.0k38.0k29.0k61.0k

Cost of goods sold

204.0k217.0k280.0k208.0k988.0k191.0k635.0k252.0k323.0k294.0k306.0k372.0k507.0k353.0k268.0k290.0k272.0k270.0k218.0k399.0k208.0k186.0k208.0k231.0k215.0k230.0k

Gross profit

(168.0k)(172.0k)(208.0k)(159.0k)(949.0k)(149.0k)(599.0k)(216.0k)(247.0k)(258.0k)(261.0k)(336.0k)(460.0k)(330.0k)(229.0k)(275.0k)(250.0k)(186.0k)(5.0k)(309.0k)(152.0k)(153.0k)(170.0k)(186.0k)(169.0k)

Gross profit Margin, %

(467%)(382%)(289%)(324%)(2433%)(355%)(1664%)(600%)(325%)(717%)(580%)(933%)(979%)(1435%)(587%)(1833%)(1136%)(221%)(2%)(343%)(271%)(464%)(447%)(641%)(277%)

R&D expense

1.6m1.8m1.7m1.7m2.4m2.3m2.3m2.2m2.3m2.3m1.9m2.7m2.4m2.0m1.0m900.0k1.3m1.4m1.1m787.0k855.0k1.3m1.6m928.0k1.1m1.2m

General and administrative expense

1.5m1.6m1.9m1.7m1.7m2.1m1.8m2.1m2.5m2.5m2.2m1.9m2.0m1.7m2.4m1.6m1.6m1.7m1.6m1.6m1.6m1.7m1.3m1.8m1.9m1.8m

Operating expense total

3.1m3.4m3.5m3.5m4.0m4.4m4.1m4.2m4.9m4.8m4.1m4.6m4.4m3.7m3.5m2.5m3.0m3.1m2.7m2.3m2.4m3.1m2.9m2.7m3.0m3.0m

EBIT

(3.2m)(3.6m)(3.7m)(3.6m)(5.0m)(4.6m)(4.7m)(4.5m)(5.1m)(5.1m)(4.3m)(4.9m)(4.9m)(4.0m)(3.7m)(2.8m)(3.2m)(3.2m)(2.7m)(2.7m)(2.6m)(3.2m)(3.0m)(2.9m)(3.2m)(3.2m)

EBIT margin, %

(9022%)(7904%)(5204%)(7414%)(12731%)(10862%)(13150%)(12386%)(6726%)(14125%)(9620%)(13675%)(10428%)(17317%)(9433%)(18760%)(14664%)(3858%)(1282%)(2947%)(4589%)(9779%)(7995%)(11117%)(5254%)

Interest expense

11.0k49.0k2.0k55.0k

Interest income

61.0k55.0k40.0k26.0k21.0k13.0k4.0k51.0k

Net Income

(2.3m)(2.7m)(2.3m)(3.0m)(6.6m)(3.6m)(4.3m)(5.1m)(3.8m)(5.0m)(4.2m)(3.4m)(4.8m)(3.8m)(2.2m)(1.3m)(2.9m)(2.8m)(2.2m)(1.3m)(2.7m)(2.4m)(3.1m)(3.4m)(2.0m)(2.9m)

AIM ImmunoTech Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.1m2.2m803.0k2.2m2.1m2.4m1.4m299.0k

Accounts Receivable

24.0k235.0k

Prepaid Expenses

531.0k322.0k358.0k399.0k335.0k610.0k880.0k

Current Assets

31.8m44.7m18.6m16.5m10.6m6.9m3.5m3.8m

PP&E

5.3m5.3m5.1m4.6m11.2m9.5m8.6m7.8m

Total Assets

43.5m57.7m31.9m29.4m22.8m18.9m14.2m13.8m

Accounts Payable

1.7m2.2m1.3m2.1m1.2m887.0k741.0k680.0k

Short-term debt

49.0k46.0k33.0k22.0k1.0k199.0k

Current Liabilities

5.1m12.6m2.5m4.4m2.4m2.4m2.7m5.3m

Long-term debt

99.0k55.0k23.0k1.8m2.3m

Total Debt

148.0k101.0k22.0k1.8m2.5m

Total Liabilities

5.5m13.0m2.6m4.4m

Common Stock

136.0k166.0k168.0k204.0k247.0k33.0k49.0k

Preferred Stock

Additional Paid-in Capital

265.0m288.7m289.6m302.7m313.2m316.0m317.4m323.7m

Retained Earnings

(226.7m)(244.1m)(260.3m)(277.8m)(293.0m)(300.5m)(308.8m)(318.6m)

Total Equity

38.0m44.7m29.3m25.0m20.4m15.5m8.7m5.2m

Debt to Equity Ratio

0 x0 x0 x0.2 x0.5 x

Debt to Assets Ratio

0 x0 x0 x0.1 x0.2 x

Financial Leverage

1.1 x1.3 x1.1 x1.2 x1.1 x1.2 x1.6 x2.7 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

2.1m4.0m3.7m2.2m3.2m1.6m1.3m1.6m4.1m2.6m1.3m2.9m1.8m1.2m1.0m1.5m4.5m776.0k1.2m503.0k4.0m3.6m4.1m2.4m959.0k9.6m

Accounts Receivable

41.0k98.0k42.0k29.0k35.0k28.0k101.0k76.0k62.0k

Prepaid Expenses

468.0k371.0k346.0k425.0k257.0k293.0k359.0k332.0k333.0k246.0k235.0k432.0k338.0k278.0k363.0k378.0k559.0k636.0k607.0k626.0k995.0k1.0m840.0k874.0k814.0k829.0k

Current Assets

33.0m34.2m33.6m30.5m36.5m38.6m32.9m29.6m21.9m20.5m17.7m17.9m17.1m14.0m9.5m10.7m9.3m5.2m4.7m3.7m5.7m5.3m4.9m5.9m3.8m12.6m

PP&E

4.8m4.7m5.1m5.3m5.3m5.1m5.0m5.1m4.9m4.8m4.7m11.8m11.7m11.5m10.9m10.1m9.8m9.3m9.0m8.8m8.4m8.1m8.0m7.6m7.5m7.3m

Total Assets

47.6m45.5m42.7m41.1m48.6m51.7m46.1m42.9m35.0m33.5m30.6m30.8m29.9m26.5m21.5m21.9m21.6m16.9m16.1m14.7m16.3m15.7m15.2m16.0m13.8m22.5m

Accounts Payable

1.1m1.6m2.5m1.8m2.3m1.7m967.0k1.7m1.2m1.5m2.4m2.3m1.6m1.5m1.4m1.4m1.0m927.0k972.0k460.0k850.0k689.0k791.0k768.0k672.0k620.0k

Short-term debt

65.0k57.0k49.0k50.0k49.0k43.0k35.0k34.0k31.0k31.0k29.0k15.0k7.0k3.0k222.0k195.0k197.0k201.0k205.0k2.3m

Current Liabilities

1.9m3.6m6.0m7.4m9.8m10.0m9.9m10.6m3.0m4.2m4.3m3.8m3.1m3.3m3.1m4.4m2.4m2.6m2.7m2.2m2.7m2.1m5.0m2.1m1.7m4.2m

Long-term debt

123.0k112.0k86.0k73.0k64.0k45.0k37.0k31.0k15.0k7.0k3.0k517.0k1.5m2.4m2.4m2.4m2.4m2.4m2.3m

Total Debt

188.0k169.0k135.0k123.0k113.0k88.0k72.0k65.0k46.0k38.0k32.0k15.0k7.0k3.0k517.0k1.5m2.7m2.6m2.6m2.6m2.6m4.6m

Total Liabilities

3.9m5.0m6.6m7.6m12.0m10.3m10.0m10.7m3.0m4.2m4.3m

Common Stock

135.0k135.0k136.0k136.0k148.0k167.0k167.0k167.0k183.0k189.0k194.0k226.0k245.0k248.0k247.0k249.0k24.0k26.0k29.0k31.0k39.0k47.0k48.0k63.0k2.0k6.0k

Preferred Stock

Additional Paid-in Capital

264.8m264.9m265.0m265.2m274.7m288.9m289.1m289.2m296.1m298.2m299.6m308.0m312.8m313.2m313.3m313.6m315.9m316.2m316.3m316.7m321.6m322.9m323.4m323.3m329.3m340.0m

Retained Earnings

(220.9m)(223.6m)(229.0m)(232.0m)(238.6m)(247.7m)(252.0m)(257.1m)(264.2m)(269.1m)(273.3m)(281.2m)(286.1m)(289.9m)(295.2m)(296.5m)(299.3m)(303.3m)(306.0m)(306.8m)(311.5m)(313.9m)(317.0m)(321.9m)(324.0m)(326.9m)

Total Equity

43.7m40.6m36.1m33.5m36.6m41.4m36.1m32.2m32.0m29.4m26.4m27.0m26.8m23.2m18.4m17.5m16.6m12.9m10.3m10.0m10.2m9.1m6.4m3.9m6.5m13.8m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0.1 x0.3 x0.3 x0.4 x0.7 x0.4 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0.2 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

1.1 x1.1 x1.2 x1.2 x1.3 x1.2 x1.3 x1.3 x1.1 x1.1 x1.2 x1.1 x1.1 x1.1 x1.2 x1.3 x1.3 x1.3 x1.6 x1.5 x1.6 x1.7 x2.4 x4.1 x2.1 x1.6 x

AIM ImmunoTech Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(9.0m)(17.4m)(16.2m)(17.4m)(15.2m)(7.5m)(8.3m)(9.8m)

Depreciation and Amortization

465.0k643.0k867.0k1.1m1.2m1.1m948.0k856.0k

Accounts Receivable

(24.0k)(1.1m)

Inventories

(110.0k)(579.0k)(1.3m)

Accounts Payable

424.0k860.0k(617.0k)869.0k(196.0k)(326.0k)566.0k166.0k

Cash From Operating Activities

(10.1m)(13.1m)(16.8m)(13.9m)(16.1m)(7.4m)(7.9m)(10.6m)

Purchases of PP&E

(1.8m)(5.8m)(898.0k)(504.0k)(240.0k)(160.0k)(20.0k)(51.0k)

Cash From Investing Activities

8.7m(16.1m)22.3m2.5m6.4m2.9m2.7m92.0k

Long-term Borrowings

(71.0k)(47.0k)(45.0k)(34.0k)(264.0k)

Dividends Paid

388.0k

Cash From Financing Activities

1.6m28.3m(6.8m)12.8m9.7m4.8m4.2m9.4m

Net Change in Cash

183.0k(891.0k)(1.4m)1.4m(41.0k)293.0k(996.0k)(1.1m)

Interest Paid

3.0k101.0k328.0k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(3.2m)(5.9m)(2.3m)(5.3m)(11.9m)(3.6m)(7.9m)(13.0m)(3.8m)(8.8m)(13.0m)(3.4m)(8.3m)(12.1m)(2.2m)(3.5m)(6.3m)(2.8m)(5.0m)(6.3m)(2.7m)(5.1m)(8.2m)(3.4m)(5.4m)(8.3m)

Depreciation and Amortization

198.0k322.0k149.0k296.0k469.0k179.0k350.0k648.0k332.0k608.0k914.0k251.0k537.0k829.0k300.0k576.0k854.0k261.0k504.0k739.0k216.0k444.0k658.0k222.0k415.0k610.0k

Accounts Receivable

(41.0k)(98.0k)(42.0k)(6.0k)(11.0k)(4.0k)(993.0k)1.0m1.0m

Inventories

(179.0k)(302.0k)(211.0k)(211.0k)(680.0k)453.0k453.0k(480.0k)(1.0m)(1.3m)

Accounts Payable

(140.0k)319.0k775.0k256.0k925.0k(358.0k)(1.0m)(197.0k)(16.0k)238.0k1.2m236.0k189.0k97.0k182.0k178.0k(202.0k)103.0k85.0k174.0k245.0k126.0k277.0k87.0k38.0k24.0k

Cash From Operating Activities

(4.8m)(7.1m)(1.7m)(5.5m)(8.2m)(5.9m)(9.6m)(13.6m)(2.9m)(6.2m)(9.9m)(4.3m)(9.2m)(12.7m)(1.0m)(2.3m)(5.3m)(3.0m)5.3m(7.2m)(2.5m)(5.2m)(8.2m)(1.5m)(4.2m)(6.8m)

Purchases of PP&E

(381.0k)(849.0k)(1.6m)(3.2m)(4.8m)(244.0k)(534.0k)(747.0k)(65.0k)(266.0k)(386.0k)(47.0k)(240.0k)(226.0k)(160.0k)(160.0k)(3.0k)(3.0k)(20.0k)(48.0k)(14.0k)(63.0k)(68.0k)

Cash From Investing Activities

4.0m7.1m1.6m1.9m(5.1m)5.2m8.8m13.1m(177.0k)(420.0k)651.0k(192.0k)(355.0k)2.1m(60.0k)1.6m2.9m486.0k1.5m1.6m1.0m993.0k1.6m(1.1m)(626.0k)(858.0k)

Long-term Borrowings

(31.0k)(50.0k)(13.0k)(25.0k)(35.0k)(13.0k)(29.0k)(36.0k)(11.0k)(18.0k)(24.0k)(7.0k)(15.0k)(19.0k)(19.0k)(97.0k)(181.0k)(84.0k)(169.0k)(254.0k)

Dividends Paid

507.0k388.0k(135.0k)(135.0k)

Cash From Financing Activities

(31.0k)1.1m569.0k2.6m13.3m(13.0k)(29.0k)(36.0k)6.4m8.4m9.7m5.2m9.3m9.7m1.0k162.0k4.7m875.0k2.6m3.6m4.1m6.4m9.3m4.7m5.5m17.0m

Net Change in Cash

(840.0k)1.1m547.0k(933.0k)55.0k(624.0k)(906.0k)(614.0k)3.3m1.8m459.0k786.0k(314.0k)(995.0k)(1.1m)(577.0k)2.4m(1.6m)(1.2m)(1.9m)2.5m2.2m2.6m2.1m660.0k9.3m

Interest Paid

(12.0k)21.0k(9.0k)(9.0k)2.0k(2.0k)(3.0k)

AIM ImmunoTech Ratios

USDY, 2019

EV/EBIT

-1.4 x

EV/CFO

-0.7 x

Financial Leverage

1.6 x

AIM ImmunoTech Employee Rating

2.110 votes
Culture & Values
2.2
Work/Life Balance
2.3
Senior Management
2.0
Salary & Benefits
1.7
Career Opportunities
1.8
Source